fda shortage list tirzepatide US judge sides with FDA's removal of Lilly's weight loss drug from May 18, 2026: FDA warns

Mouse redox histology using genetically encoded probes

GLP-1 class safety monitoring should include awareness of these important risks: Pancreatitis : Patients should promptly report severe abdominal pain, with or without vomiting Gallbladder disease : Report symptoms of biliary colic or cholecystitis Acute kidney injury : Maintain adequate hydration, especially if experiencing nausea/vomiting Hypoglycemia : Increased risk when used with insulin or sulfonylureas Suicidal ideation : For patients using Wegovy or Zepbound, monitor for mood changes Patients should be counseled to report any neck swelling, difficulty swallowing, persistent hoarseness, or palpable thyroid nodules, as these warrant evaluation regardless of GLP-1 use

developed nano-emulgels and nano-emulsions as an alternative to oral administration that facilitated the transdermal distribution of statins

Tirzepatide (PlexusDx compounded version is $289/mo month-to-month, or from $249/mo on the 6-month plan) activates both GLP-1 and GIP receptors, offering a different mechanism that some patients tolerate better